All In Biotech

Drug Trial Radar · NCT02500407

A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

An Open-Label, Multicenter, Phase I/II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Escalating Doses of Mosunetuzumab (BTCT4465A) as a Single Agent and Combined With Atezolizumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Last checked: Nov 20, 2026Latest source record: Sep 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

713

Actual

Start

Sep 15, 2015

Primary completion

May 21, 2024

Study completion Sep 1, 2025

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jul 16, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2 dose-escalation study of BTCT4465A (Mosunetuzumab) administered as a single agent and in combination with atezolizumab in participants with relapsed or refractory B-cell NHL and CLL. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

Conditions

  • Lymphocytic Leukemia, Chronic
  • Lymphoma, Non Hodgkin

Interventions

  • BTCT4465A (Mosunetuzumab) IVDrug

    Participants with B-cell NHL and CLL will receive BTCT4465A (Mosunetuzumab) via IV infusion.

  • AtezolizumabDrug

    Participants assigned to an atezolizumab combination group will receive atezolizumab 1200 mg administered as an IV infusion in combination with BTCT4465A (Mosunetuzumab).

  • BTCT4465A (Mosunetuzumab) SCDrug

    Participants with B-cell NHL and CLL will receive BTCT4465A (Mosunetuzumab) via SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose (MTD) of BTCT4465A (Mosunetuzumab)Time frame: BTCT4465A (Mosunetuzumab) single agent: Cycle 1; BTCT4465A (Mosunetuzumab) in combination with atezolizumab: during the first cycle that BTCT4465A (Mosunetuzumab) and atezolizumab are administered concurrently (cycle length = 21 days)
  2. Percentage of Participants With Adverse EventsTime frame: Cycle 1 Day 1 until 90 days after the last infusion (cycle length = 21 days; up to approximately 14 months)
  3. BTCT4465A (Mosunetuzumab) Serum ConcentrationTime frame: Baseline up to 30 days after the last infusion of BTCT4465A (Mosunetuzumab) (up to approximately 12 months)
  4. Atezolizumab Serum ConcentrationTime frame: Baseline up to 30 days after the last infusion of BTCT4465A (Mosunetuzumab) (up to approximately 12 months)
  5. Percentage of Participants with Complete Response as Assessed Using Standard Criteria for NHLTime frame: Baseline up to approximately 4 years (assessed at screening and then every 3 months until disease progression, start of new anti-cancer therapy, or withdrawal)

Locations

35 sites in 7 countries. Site status is shown where the registry gives one.

  • University of California San Diego Moores Cancer Center

    La Jolla, California

  • Sansum Medical Clinic, Inc.

    Santa Barbara, California

  • Rocky Mountain Cancer Center

    Denver, Colorado

  • Yale University School Of Medicine

    New Haven, Connecticut

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Memorial Sloan Kettering Bergen

    Montvale, New Jersey

  • Memorial Sloan Kettering Cancer Center - Commack

    Commack, New York

  • Memorial Sloan Kettering Cancer Center at Westchester

    Harrison, New York

  • New York Uni Medical Center

    New York, New York

  • Willamette Valley Cancer Insitute and Research Center

    Springfield, Oregon

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • MD Anderson Cancer Center

    Houston, Texas

  • St Vincent's Hospital Sydney

    Darlinghurst, New South Wales, Australia

  • Icon Cancer Care South Brisbane

    South Brisbane, Queensland, Australia

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • St. Vincent's Hospital Melbourne

    Fitzroy, South Australia, Australia

  • Royal Hobart Hospital

    Hobart, Tasmania, Australia

  • Monash Health Clinical Trial Pharmacy department

    Clayton, Victoria, Australia

  • The Perth Blood Institute

    Nedlands, Western Australia, Australia

  • Princess Margaret Hospital

    Toronto, Ontario, Canada

  • Jewish General Hospital

    Montreal, Quebec, Canada

  • Universitatsklinikum Koln

    Cologne, Germany

  • Universitätsklinikum Heidelberg

    Heidelberg, Germany

  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz

    Mainz, Germany

  • Klinikum der Universität München, Campus Großhadern

    München, Germany

  • Seoul National University Hospital

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Hospital Universitario Vall d Hebron

    Barcelona, Spain

  • Hospital Universitario La Paz

    Madrid, Spain

  • Complejo Asistencial Universitario de Salamanca

    Salamanca, Spain

  • Clínica Universidad de Navarra

    Pamplona, Navarre, Spain

  • Barts Cancer Institute

    London, United Kingdom

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom

  • Royal Marsden Hospital;Institute of Cancer Research

    Sutton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.